Tralokinumab - Leo Pharma

Drug Profile

Tralokinumab - Leo Pharma

Alternative Names: CAT-354

Latest Information Update: 20 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Icahn School of Medicine at Mount Sinai; LEO Pharma; MedImmune
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Alopecia areata
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 18 Jul 2018 Phase-III clinical trials in Atopic dermatitis (In adolescents, Monotherapy) in USA (SC) (NCT03526861)
  • 16 Jul 2018 LEO Pharma plans the phase III ECZTEND trial for Atopic Dermatitis (NCT03587805)
  • 13 Jul 2018 Phase-II clinical trials in Atopic dermatitis in USA (SC) (NCT03562377)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top